PYMX MNTA: As noted in reply to your post on SI (http://siliconinvestor.advfn.com/readmsg.aspx?msgid=26587522 ), the cumbersome process that’s apparently required for PMX-60056 to reverse Lovenox is a boost, albeit a small one, for MNTA’s M118, which can be fully reversed with protamine (#msg-39146357). I consider this a small boost for M118 rather than a big boost because the target market for M118 is ACS and Lovenox is not a big factor in that market.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”